Loading
A phase 2 trial of Somatostatin receptor PET in Neuroendocrine tumours, run by Rigshospitalet, Denmark, with a status the registry has not verified recently.
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms is a phase 2 interventional study registered as NCT05709171 by Rigshospitalet, Denmark, with 200 participants planned, started 2023-01-17 and due to reach its primary completion in 2025-01-01. Interventions recorded: 18F-FDG, 64Cu-Dotatate. Conditions recorded: GEP-NET, Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma Metastatic.
Linked to the technology Somatostatin receptor PET because the registry names it ("64cu dotatate") among its interventions and Neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.
Shares Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.